Natera Inc
NASDAQ:NTRA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
52.51
169.36
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NTRA stock under the Base Case scenario is 56.65 USD. Compared to the current market price of 167.26 USD, Natera Inc is Overvalued by 66%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Natera Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NTRA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Natera Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Natera Inc. is a leading genomics company that specializes in genetic testing and precision medicine, aiming to revolutionize healthcare through advanced DNA analysis. Founded in 2004 and headquartered in Austin, Texas, Natera focuses on reproductive health, oncology, and organ transplant management, providing invaluable insights that help doctors make informed decisions for their patients. Its flagship products include non-invasive prenatal testing (NIPT), which has gained significant traction for its ability to assess fetal health with remarkable accuracy, along with tests for hereditary cancer risk and monitoring treatment response in cancer patients. By harnessing the power of next-gener...
Natera Inc. is a leading genomics company that specializes in genetic testing and precision medicine, aiming to revolutionize healthcare through advanced DNA analysis. Founded in 2004 and headquartered in Austin, Texas, Natera focuses on reproductive health, oncology, and organ transplant management, providing invaluable insights that help doctors make informed decisions for their patients. Its flagship products include non-invasive prenatal testing (NIPT), which has gained significant traction for its ability to assess fetal health with remarkable accuracy, along with tests for hereditary cancer risk and monitoring treatment response in cancer patients. By harnessing the power of next-generation sequencing and machine learning, Natera is positioned to disrupt traditional medical practices and improve patient outcomes.
Investors looking at Natera will find a company poised for growth amid increasing demand for genetic testing and personalized medicine. The company benefits from a robust pipeline and an expanding customer base, bolstered by strategic collaborations with healthcare providers and insurance companies. As awareness of genetic testing continues to rise, Natera's innovative solutions could capture substantial market share, particularly in oncology, where early detection can dramatically impact treatment efficacy and survival rates. With strong financial backing, a commitment to research and development, and a vision to elevate the standard of care through data-driven insights, Natera represents a compelling opportunity for those seeking to invest in the future of healthcare.
Natera Inc. operates primarily within the field of genetic testing and diagnostics, focusing on several core business segments. Here are the key areas:
-
Women’s Health: This segment includes prenatal testing services that assess the genetic health of a fetus. Natera's tests, such as the Panorama test, are designed to screen for chromosomal abnormalities like Down syndrome and other genetic conditions.
-
Oncology: Natera offers a range of tests aimed at cancer detection and monitoring. Their Signatera test is a personalized circulating tumor DNA (ctDNA) assessment that helps in monitoring treatment efficacy and detecting minimal residual disease (MRD) in cancer patients.
-
Transplantation: This segment involves tests that assess transplant organ compatibility and monitor transplant rejection. Natera's Prospera test evaluates kidney transplant patients to determine the risk of rejection by analyzing donor-derived cell-free DNA.
-
Pediatric and Rare Diseases: Natera offers genetic testing services that screen for a range of pediatric and rare genetic disorders. These tests help in the early diagnosis of conditions that could benefit from timely intervention.
-
Research and Development: Although not a standalone revenue segment, Natera invests significantly in R&D to advance its testing technologies and expand its product offerings in both existing and new markets.
Overall, Natera's focus is on using advanced genetic technologies to provide comprehensive solutions in the fields of reproductive health, oncology, organ transplantation, and rare disease diagnosis. This diversified approach helps the company cater to a wide range of healthcare needs, expanding its market potential and resilience.
Natera Inc. holds several unique competitive advantages that position it favorably against its rivals in the genetic testing and diagnostics industry:
-
Comprehensive Product Range: Natera offers a broad spectrum of tests, including non-invasive prenatal testing (NIPT), oncology, carrier screening, and organ transplant testing. This diverse portfolio allows the company to cater to various segments of the healthcare market.
-
Advanced Technology and Innovation: Natera has developed proprietary technologies, such as its Next Generation Sequencing (NGS) capabilities, which enhance the accuracy and reliability of its tests. Their technology enables the detection of even low-frequency genetic variants, providing detailed insights.
-
Strong Clinical Validation: Natera’s tests are backed by extensive clinical validation studies. This not only reinforces their credibility but also instills trust among healthcare providers and patients. Their focus on evidence-based testing strengthens their position in the market.
-
Partnerships and Collaborations: The company has established significant partnerships with healthcare institutions and payers, enhancing their distribution channels and fostering trust within the healthcare ecosystem. Collaborations for research and development also drive innovation.
-
Focus on Outcome-Based Care: Natera emphasizes improving patient outcomes through its tests, particularly in oncology. Their focus on precision medicine allows for tailored treatment strategies, which can lead to better health outcomes, setting them apart from competitors.
-
Data-Driven Insights: Natera leverages vast datasets to enhance its test offerings and improve diagnostic accuracy. By utilizing real-world data, they can adapt and refine their products continuously, ensuring they remain at the forefront of genetic testing.
-
Regulatory Approval and Reimbursement Landscape: Natera has successfully navigated the regulatory landscape and gained necessary approvals for its tests, which can be a barrier for new entrants. Furthermore, their tests are often covered by insurance, facilitating accessibility for patients.
-
Direct-to-Consumer (DTC) Approach: Natera's strategies extend into the DTC market, allowing for greater reach and engagement with consumers. This approach can lead to increased brand loyalty and market share.
-
Strong Brand Reputation: Over the years, Natera has built a reputable brand, particularly in the prenatal testing market. A strong reputation can significantly influence purchasing decisions, giving Natera an edge over competitors.
-
Global Expansion Opportunities: While Natera has a strong presence in the U.S., it is also expanding internationally. This growth potential in emerging markets can lead to new revenue streams and reduced dependency on any single market.
These advantages collectively help Natera differentiate itself in a competitive landscape, allowing it to capture market share and drive growth effectively.
Natera Inc, a leader in genetic testing and diagnostics, faces several risks and challenges in the near future:
-
Regulatory Challenges: As a healthcare-related company, Natera is subject to rigorous FDA regulations and changes in healthcare policy. Any alterations in regulations or potential changes to reimbursement rates can impact profitability.
-
Competition: The genetic testing market is highly competitive, with numerous companies offering similar services. Emerging competitors with innovative technologies could potentially take market share.
-
Technological Advancements: Rapid advancements in genetic testing technology necessitate continuous innovation. Failing to keep pace could result in losing relevance or market share.
-
Reimbursement Issues: Changes in insurance reimbursement policies or the acceptance of genetic tests by payers could limit patient access to their services, impacting revenue.
-
Market Adoption: While demand for genetic testing is growing, convincing healthcare providers and patients to adopt new tests may be challenging, particularly in conservative medical communities.
-
Operational Scalability: As the company grows, scaling operations efficiently while maintaining quality control and service delivery could pose a significant challenge.
-
Data Privacy and Security: Given the sensitive nature of genetic information, maintaining robust data security practices is crucial. Any breach could harm reputation and result in legal repercussions.
-
Economic Factors: Broader economic conditions, such as recessions or shifts in consumer spending, could impact patients' willingness or ability to pay for genetic testing.
-
Intellectual Property Risks: Protecting proprietary technologies and ensuring that they are not infringed upon by competitors can be an ongoing challenge.
-
Investor Sentiment: As a publicly traded company, Natera’s stock performance can be influenced by market sentiment, which can be volatile and affect its capacity to raise capital.
Each of these factors must be monitored closely, as they can significantly impact Natera's strategic positioning and financial performance in the coming quarters.
Revenue & Expenses Breakdown
Natera Inc
Balance Sheet Decomposition
Natera Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 922.3m |
Receivables | 306.9m |
Other Current Assets | 93.4m |
Non-Current Assets | 268.4m |
PP&E | 230m |
Other Non-Current Assets | 38.4m |
Current Liabilities | 301.4m |
Accounts Payable | 27.8m |
Accrued Liabilities | 159.4m |
Short-Term Debt | 80.5m |
Other Current Liabilities | 33.7m |
Non-Current Liabilities | 411m |
Long-Term Debt | 286.5m |
Other Non-Current Liabilities | 124.5m |
Earnings Waterfall
Natera Inc
Revenue
|
1.5B
USD
|
Cost of Revenue
|
-648.6m
USD
|
Gross Profit
|
883.4m
USD
|
Operating Expenses
|
-1.1B
USD
|
Operating Income
|
-242.1m
USD
|
Other Expenses
|
27.4m
USD
|
Net Income
|
-214.7m
USD
|
Free Cash Flow Analysis
Natera Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Natera reported a remarkable 64% year-over-year revenue increase, reaching $439.8 million, driven by a 24% rise in test volumes. Signatera clinical units surged by over 48,000 units year-on-year. With gross margins at a record 62%, the company generated $34.5 million in cash. Natera now anticipates full-year revenues between $1.61 billion and $1.64 billion, reflecting a growth rate of about 50%. Looking ahead, they aim to maintain similar test volumes in 2025 while focusing on expanding their oncology presence and enhancing service capabilities.
What is Earnings Call?
NTRA Profitability Score
Profitability Due Diligence
Natera Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Natera Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
NTRA Solvency Score
Solvency Due Diligence
Natera Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Natera Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTRA Price Targets Summary
Natera Inc
According to Wall Street analysts, the average 1-year price target for NTRA is 174.82 USD with a low forecast of 136.35 USD and a high forecast of 219.45 USD.
Dividends
Current shareholder yield for NTRA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NTRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 2,670 full-time employees. The company went IPO on 2015-07-02. The Company’s cell-free deoxyribonucleic acid (DNA) or (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The firm's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The firm also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.
Contact
IPO
Employees
Officers
The intrinsic value of one NTRA stock under the Base Case scenario is 56.65 USD.
Compared to the current market price of 167.26 USD, Natera Inc is Overvalued by 66%.